MPS1 inhibition primes immunogenicity of KRAS-LKB1 mutant lung cancer
Shunsuke Kitajima(Dana-Farber Cancer Institute), Tetsuo Tani(Dana-Farber Cancer Institute), Benjamin F. Springer(Dana-Farber Cancer Institute), Marco Campisi(Dana-Farber Cancer Institute), Tatsuya Osaki(Tokyo Institute of Technology), Koji Haratani(Dana-Farber Cancer Institute), Minyue Chen(Dana-Farber Cancer Institute), Erik H. Knelson(Dana-Farber Cancer Institute), Navin R. Mahadevan(Dana-Farber Brigham Cancer Center), Jessica Ritter(Dana-Farber Brigham Cancer Center), Ryohei Yoshida(Dana-Farber Cancer Institute), Jens Köhler(Dana-Farber Cancer Institute), Atsuko Ogino(Dana-Farber Cancer Institute), Ryu‐Suke Nozawa(Japanese Foundation For Cancer Research), Shriram K. Sundararaman(Beth Israel Deaconess Medical Center), Tran C. Thai(Dana-Farber Cancer Institute), Mizuki Homme(Japanese Foundation For Cancer Research), Brandon Piel(Dana-Farber Cancer Institute), Sophie Kivlehan(Dana-Farber Cancer Institute), Bonje Obua(Dana-Farber Cancer Institute), Connor Purcell(Dana-Farber Cancer Institute), Mamiko Yajima(Brown University), Thanh U. Barbie(Dana-Farber Brigham Cancer Center), Patrick H. Lizotte(Dana-Farber Cancer Institute), Pasi A. Jänne(Dana-Farber Cancer Institute), Cloud P. Paweletz(Dana-Farber Cancer Institute), Prafulla C. Gokhale(Dana-Farber Cancer Institute), David A. Barbie(Dana-Farber Cancer Institute)
Cited by 100Open Access